{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-031135","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.681299+00:00","generated_at":"2026-06-18T05:18:45.074451+00:00","sec_items":["7.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Protagonist Therapeutics discloses limited SVB exposure, $13M at risk out of $231M total","bullets":["Cash at SVB approximately $13M as of March 9, 2023; company considers exposure limited.","Third-party investments of ~$218M held at multiple custodians are not directly exposed to SVB liquidity concerns.","Total cash and investments approximately $231M; company notes multiple custodians reduce risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-031135","json":"https://secwatch.observer/filing/0001104659-23-031135.json","markdown":"https://secwatch.observer/filing/0001104659-23-031135.md","text":"https://secwatch.observer/filing/0001104659-23-031135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923031135/0001104659-23-031135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465923031135/tm239184d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T05:18:45.074451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}